FGK Clinical Research GmbH
FGK Clinical Research GmbH is a Europe-based Contract Research Organization with offices in Germany (HQs in Munich, branch office in Berlin), Poland, Czech Republic and Hungary. We provide full service for Phase I–IV clinical studies. Our international client base includes biotechnology, medical device and pharmaceutical companies.
FGK has the right size to handle multi-country, multicenter studies with hundreds of patients or single country studies with a few patients, but is still small enough to guarantee a personal service to the sponsor. With our 230 highly qualified medical, scientific and regulatory experts, we have all the knowledge and experience to guide our clients through the clinical trial process, from planning and approval to the final report.
FGK Clinical Research at a glance:
Field of Activity | Contract research organization offering a complete range of clinical development and consulting services to biotech, medical device and pharmaceutical companies. |
Partners | We work with a network of carefully selected companies to complement our own services. This allows us to operate across border and provide services required for drug development and performance of multinational clinical trials. We are also able to offer eSolutions. |
Services |
|
Unique Selling Point | As an owner-driven CRO for more than 20 years now, we are specialized in the collaboration with biotech and medical device companies. FGK has very fast decision ways and is extremely flexible. As the fluctuation rate has been constantly low, knowledge and experience of staff members stay at FGK in the long run. |
Membership in networks/associations | BVMA, Bio Deutschland, ImmPact Bavaria |
Date of Incorporation/Number of Employees | 2002/approx. 230 |
Contact:
Address | Heimeranstrasse 35 80339 Munich |
Telephone/Telefax | +49 89 893 119-0/-20 |
info@fgk-cro.com | |
Web Address | www.fgk-cro.com |
- Zell- und Gentherapien in Leipzig: Stärker durch Vernetzung
- Revolutionäre Ansätze in der Medizin
- AC Immune erhält FDA Fast Track Designation für Alzheimer-Impfstoff
- Biotech & Co. Basket zeigt ein gemischtes Bild
- Investment: Life-Sciences-Sektor ist resilient, aber nicht immun
- „Wer aktuell eine Finanzierung anstrebt, sollte es nicht zu eilig haben“
- Affimed präsentiert neue AFM13-Daten
- Marinomed Biotech AG – Wiener Biopharmazie mit großer Pipeline
- Affimed N.V.: Lohnt sich ein Investment?
- Convergence Partners investiert in Clerkenwell Health
- „Man wird auch in Zukunft nicht auf klassische klinische Studien verzichten können”
- Climedo Health sichert siebenstellige Seed-Finanzierungsrunde
- Wichtige Wege zum Erfolg
- Mondosano schließt millionenschwere Finanzierung ab
- Medigene AG: Erhöhung der Gesamterlöse um 43% auf 9,8 Mio. EUR
- Deutschland weltweit Nr. 2 bei klinischen Studien